Xingyingying

Dr. Xing focuses on Biotechnology drug at School of Life Science and Technology, China Pharmaceutical University. Holding a Ph.D. in Marine pharmacy from CPU. Dr. Xing specializes in  recombinant protein vaccines, mRNA(circRNA )vaccines against bacterial infections(Helicobacter pylori）and tumors.

(1) Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375/PRKDC Axis and PD-L1 phosphorylation, Molecular Cancer, 2023 ;

(2) Protonated Charge Reversal Nanodrugs for Active Targeting

Clearance of Helicobacter Pylori Accompanied by Gut

Microbiota Protection, Advance Function Materials, 2023；

(3) MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis, STEM CELL RESEARCH

 & THERAPY, 2021; 

Silk fibroin hydrogel as mucosal vaccine carrier: induction of gastric CD4+TRM cells mediated by inflammatory response induces optimal immune protection against Helicobacter felis, Emerging Microbes & Infections, 2020;

(1) The forming mechanism and protective efficacy: tissue-

resident memory T cells emerge after gastric subserous vaccination with Helicobacter pylori vaccine CCF; National Natural Science Foundation of China (No. 81971562);

(2) Research and development of biotechnology drugs and rapid diagnostic techniques for Helicobacter pylori infected gastric diseases; Key R&D Plan Project of Ningxia Autonomous Region (No. 2020BFG02012);

(3) Research and development of mRNA and circRNA vaccine against Helicobacter pylori；Health Science and Technology Innovation joint project of Hainan Province (No.  WSJK2024MS230); 

Marine Nature Products Chemistry